Prothena reported $542.99M in Cash and Equivalent for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cash And Equivalent Change
Acadia Pharmaceuticals ACAD:US $ 204.92M 57.48M
Agios Pharmaceuticals AGIO:US $ 80.03M 123.1M
Akebia Therapeutics AKBA:US $ 174.56M 24.76M
ALKERMES ALKS:US $ 282.56M 54.99M
Alnylam Pharmaceuticals ALNY:US $ 534.08M 285.89M
Amgen AMGN:US $ 6528M 1461M
Biogen BIIB:US $ 1749.3M 512.1M
Biomarin Pharmaceutical BMRN:US $ 605.44M 18.16M
Bluebird Bio BLUE:US $ 106.26M 54.9M
Exelixis EXEL:US $ 723.27M 76.1M
Intercept Pharmaceuticals ICPT:US $ 48.32M 36.39M
Intra Cellular Therapies ITCI:US $ 129.29M 36.93M
IONIS PHARMACEUT IONS:US $ 542.51M 326.68M
Macrogenics MGNX:US $ 47.33M 76.14M
Nektar Therapeutics NKTR:US $ 67.99M 42.78M
Neurocrine Biosciences NBIX:US $ 270.2M 70.6M
Prothena PRTA:US $ 542.99M 36.1M
Regeneron Pharmaceuticals REGN:US $ 3345.7M 460.1M
Seattle Genetics SGEN:US $ 261M 163.84M
Ultragenyx Pharmaceutical RARE:US $ 153.99M 153.6M
Vertex Pharmaceuticals VRTX:US $ 7600.1M 805.1M
Vital Therapies VTL:US $ 95.71M 8.85M
YTE INCY:US $ 2256.76M 199.32M